Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients.
S100B
chronic migraine
trigemino-vascular system
Journal
Headache
ISSN: 1526-4610
Titre abrégé: Headache
Pays: United States
ID NLM: 2985091R
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
07
05
2020
revised:
25
06
2020
accepted:
25
06
2020
pubmed:
18
8
2020
medline:
9
11
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
The trigemino-vascular system (TVS) plays a key role in migraine pathophysiology. Glial cells are abundant in the TVS system and mainly in the trigeminal ganglion. S100B protein is a calcium-binding protein, found in the cytoplasm of glial cells in the central nervous system, which is released in response to inflammatory stimuli. Previous works analyzing S100B in migraineurs have offered contradictory results. In this case-control study, we analyzed serum levels of S100B as a possible biomarker of the glial TVS activation in chronic migraine (CM). The study group consisted of patients attending our clinic with CM and, as control groups, patients with episodic migraine (EM), cluster headache (CH) outside of a bout and healthy volunteers (HV) with no headache history. S100B levels were determined interictally in peripheral blood samples by ELISA. We assessed serum samples from 43 patients with CM, 19 with EM, 29 HV (mostly women), and 22 with (CH). S100B levels in CM (mean 22.9 ± 9.8 pg/mL) were not different (P = .727) when compared to EM patients (21.2 ± 9.3 pg/mL), difference of 1.7 (95% CI -5.7 to 8.9), CH patients (22.4 ± 7.8 pg/mL), difference of 0.5 (-5.7 to 6.7), and HV (20.6 ± 8.3 pg/mL), difference of 2.3 (-3.7 to 8.3). In contrast to other neuropeptides such as calcitonin gene-related-peptide and vasoactive intestinal peptide, which are increased in CM, interictal serum S100B levels are not elevated in these patients. According to our results, S100B levels do not seem to be a useful peripheral biomarker of the glial TVS activation in CM.
Sections du résumé
BACKGROUND
BACKGROUND
The trigemino-vascular system (TVS) plays a key role in migraine pathophysiology. Glial cells are abundant in the TVS system and mainly in the trigeminal ganglion. S100B protein is a calcium-binding protein, found in the cytoplasm of glial cells in the central nervous system, which is released in response to inflammatory stimuli. Previous works analyzing S100B in migraineurs have offered contradictory results.
OBJECTIVE
OBJECTIVE
In this case-control study, we analyzed serum levels of S100B as a possible biomarker of the glial TVS activation in chronic migraine (CM).
PATIENTS AND METHODS
METHODS
The study group consisted of patients attending our clinic with CM and, as control groups, patients with episodic migraine (EM), cluster headache (CH) outside of a bout and healthy volunteers (HV) with no headache history. S100B levels were determined interictally in peripheral blood samples by ELISA.
RESULTS
RESULTS
We assessed serum samples from 43 patients with CM, 19 with EM, 29 HV (mostly women), and 22 with (CH). S100B levels in CM (mean 22.9 ± 9.8 pg/mL) were not different (P = .727) when compared to EM patients (21.2 ± 9.3 pg/mL), difference of 1.7 (95% CI -5.7 to 8.9), CH patients (22.4 ± 7.8 pg/mL), difference of 0.5 (-5.7 to 6.7), and HV (20.6 ± 8.3 pg/mL), difference of 2.3 (-3.7 to 8.3).
CONCLUSION
CONCLUSIONS
In contrast to other neuropeptides such as calcitonin gene-related-peptide and vasoactive intestinal peptide, which are increased in CM, interictal serum S100B levels are not elevated in these patients. According to our results, S100B levels do not seem to be a useful peripheral biomarker of the glial TVS activation in CM.
Substances chimiques
Biomarkers
0
S100 Calcium Binding Protein beta Subunit
0
S100B protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1705-1711Subventions
Organisme : Instituto de Salud Carlos III
ID : Pl14/00020
Informations de copyright
© 2020 American Headache Society.
Références
Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.
May A, Schulte LH. Chronic migraine: Risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455-464.
Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002;346:257-270.
Goadsby PG. Autonomic nervous system control of the cerebral circulation. Handbook Clin Neurol. 2013;117:193-201.
Rodríguez-Osorio X, Sobrino T, Brea D, Martínez F, Castillo J, Leira R. Endothelial progenitor cells: A new key for endotelial dysfunction in migraine. Neurology. 2012;79:474-479.
Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker of chronic migraine. Neurology. 2013;81:1191-1196.
Domínguez C, Vieites-Prado A, Pérez-Mato M, et al. CGRP and PTX3 as predictors of efficacy of onabotulinumtoxin type A in chronic migraine: An observation study. Headache. 2018;58:78-87.
Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015;35:310-316.
Capuano A, De Corato A, Lisi L, et al. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: Relevance for migraine pathology. Mol Pain. 2009;5:43-55.
Thalakoti S, Patil VV, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: Implications for migraine pathology. Headache. 2007;47:1008-1023.
Dublin P, Hanani M. Satellite glial cells in sensory ganglia: Their possible contribution to inflammatory pain. Brain Behav Immunol. 2007;21:592-598.
Papandreou O, Soldatou A, Tsitisika A, et al. Serum S100 beta protein in children with acute recurrent headache: A potentially useful marker for migraine. Headache. 2005;45:1313-1316.
Teepker M, Munk K, Mylius V, et al. Serum concentration of s100b and NSE in migraine. Headache. 2009;49:245-252.
Yilmaz N, Karsali K, Ordem S, et al. Elevated S100B and neuron specific enolase levels in patients with migraine-without aura: Evidence for neurodegeneration? Cell Mol Neurobiol. 2011;31:579-585.
Celikbilek A, Sabah S, Tanik N, et al. Is serum S100B protein an useful biomarker in migraine? Neurol Sci. 2014;35:1197-1201.
Cernuda-Morrollon E, Riesco N, Martínez-Camblor P, Serrano-Pertierra E, García-Cabo C, Pascual J. No change in interictal PACAP levels in peripheral blood in women with chronic migraine. Headache. 2016;56:1448-1454.
Guo S, Haulund AL, Lee YB, et al. Biochemichal changes after pituitary adenylate cylase-activating polypeptide-38 infusion in migraine patients. Cephalalgia. 2017;37:136-147.
Donato R. Functional roles of S100 proteins, calcium binding proteins of the EF-hand type. Biochim Biophys Acta. 1999;1450:191-231.
Jonsson H, Johnsson P, Hoglund P, et al. Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth. 2000;14:698-701.
Ingebrigtsen T, Romner B, Marup-Jensen S, et al. The clinical value of serum S-100 protein measurements in minor head injury: A Scandinavian multicentre study. Brain Inj. 2000;14:1047-1055.
Jauch EC, Lindsell C, Broderick J, et al. Association of serial biochemical markers with acute ischemic stroke: The National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study. Stroke. 2006;37:2508-2513.
Bartosik-Psujek H, Psujek M, Jaworski J, et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone. Acta Neurol Scand. 2011;123:252-256.
Schaf DV, Tort AB, Fricke D, et al. S100B and NSE serum levels in patients with Parkinson's disease. Parkinsonism Relat Disord. 2005;11:39-43.
Bloomfield SM, McKinney J, Smith L, et al. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care. 2007;6:121-138.
Kapural M, Krizanac-Bengez L, Barnett G, et al. Serum S-100beta as a possible marker of blood-brain barrier disruption. Brain Res. 2002;940:102-104.
Amin FM, Hougaard A, Cramer SP, et al. Intact blood-brain barrier during spontaneous attacks of migraine without aura: A 3T DCE-MRI study. Eur J Neurol. 2017;24:1116-1124.
Hougaard A, Amin FM, Christensen CE, et al. Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain. 2017;140:1633-1642.
Eftekhari S, Salvatore CA, Johanson S, Chen T, Zeng Z, Edvinsson L. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood-brain barrier. Brain Res. 2015;1600:93-109.
Plog BA, Dashnaw ML, Hitomi E, et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci. 2015;35:518-526.
Lindblad C, Nelson DW, Zeiler FA, et al. Influence of blood-brain barrier integrity on brain protein biomarker clearance in severe traumatic brain injury: A longitudinal prospective study. J Neurotrauma. 2020;37:1381-1391.
Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The glymphatic system: A beginner's guide. Neurochem Res. 2015;40:2583-2599.
Schain AJ, Melo-Carrillo A, Strassman AM, Burstein R. Cortical spreading depression closes paravascular space and impair glymphatic flow: Implications for migraine headache. J Neurosci. 2017;37:2904-2915.
Fulle S, Pietrangelo T, Mariggiò MA, et al. Calcium and fos involvement in brain-derived Ca2+ -binding protein (S100)-dependent apoptosis in rat phaeochromocytoma cells. Exp Physiol. 2000;85:243-253.
Lee MJ, Lee SY, Cho S, Kang ES, Chung CS. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: A critical reappraisal. J Headache Pain. 2018;19. doi:10.1186/s10194-018-0883-x.